SWX:SKANLife Sciences
SKAN Group (SWX:SKAN) Stock Richly Valued As Margin Recovery Lags Backlog Growth
SKAN Group stock has been on a tear into this earnings print, closing at CHF62.70 and logging a roughly 32% gain over the past three months. That kind of run sets a high bar for a specialised pharma equipment supplier.
The headline from H1 is clear. SKAN Group delivered a sharp reset in profitability with net profit of CHF5.4m and an EBITDA margin of 9.3% on CHF164.5m of net sales. Order intake of CHF247.6m and a CHF442m backlog reflect why the growth story still commands a premium P/E...